The World Vaccine Congress Europe 2026 is a premier global event focused on vaccines, immunotherapy, and infectious disease research in Europe. Importantly, it convenes leaders from pharmaceuticals, biotechnology, academia, regulators, and public health organizations. Together, they share knowledge, explore innovations, and discuss strategies for vaccine development, manufacturing, and distribution. As a result, the congress is recognized as one of the world’s leading vaccine-focused events. Consequently, it serves as a strategic platform for scientific exchange, collaboration, and business development.
In 2026, the congress will address key topics shaping the vaccine landscape. Specifically, these include novel technologies, mRNA and viral vector platforms, adjuvants, and immuno-oncology vaccines. In addition, sessions will cover clinical development strategies, regulatory frameworks, pandemic preparedness, and large-scale manufacturing solutions. Furthermore, discussions will explore global health initiatives, AI-driven research, advanced analytics, and supply-chain resilience. Overall, these themes highlight the intersection of innovation, policy, and practical vaccine delivery.
Typically, attendees include vaccine developers, pharmaceutical and biotech executives, and clinical researchers. Moreover, immunologists, regulatory experts, policy leaders, public health officials, and investors are well represented. As a result, participants can network, form collaborations, and gain insights into emerging trends and regulatory expectations. Notably, these insights span both European and global markets.
Finally, the congress offers strong opportunities to showcase technologies and explore partnership or licensing opportunities. Additionally, companies gain direct access to key decision-makers across the vaccine ecosystem. Key industries represented include biotechnology, pharmaceutical manufacturing, CROs, diagnostics, and public health organizations. By uniting the full stakeholder spectrum, the 2026 congress aims to accelerate innovation and strengthen global vaccination strategies.
